Molecular PartnersMOLN
About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Employees: 167
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
61% more capital invested
Capital invested by funds: $3.83M [Q1] → $6.18M (+$2.35M) [Q2]
0% more funds holding
Funds holding: 8 [Q1] → 8 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.26% less ownership
Funds ownership: 2.6% [Q1] → 2.35% (-0.26%) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for MOLN.